In autistic children given oxytocin, a smaller placebo response during the lead-in phase was associated with a larger response during active treatment.
In plain wordsIn autistic children given oxytocin, a smaller response to placebo before treatment was linked to a larger response during oxytocin treatment.
- Peptide
- Oxytocin
- Outcome
- Not applicableAssociation between placebo response and oxytocin treatment response
- Study
n: not reported in source
- Outcome group
- Anxiety and mood · Mental health and mood
- Studied dose
- Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Smaller placebo responses during the lead-in phase were associated with larger responses during active treatment in participants receiving oxytocin (r = -.36, p = .017).
2 context sentences(design, population, supporting numbers)
Eighty-seven autistic children aged 3-12 years (M = 7.27; SD = 2.69; 85.1% male) were consecutively recruited into a multi-site RCT evaluating the efficacy of oxytocin for improving social responsiveness.
Participants underwent a 3-week, single-blind placebo lead-in before randomisation into a 12-week double-blind treatment phase (oxytocin, n = 45; placebo, n = 42).